• Delfi Diagnostics Marries Fragmentomics, Machine Learning in Cancer Detection

  • 2024/11/21
  • 再生時間： 58 分
  • ポッドキャスト

Delfi Diagnostics Marries Fragmentomics, Machine Learning in Cancer Detection

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • “Our mission is to make cancer less deadly through widely accessible next-generation early-detection blood tests.” Susan Tousi, CEO of Delfi Diagnostics, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Tousi joins BI analyst Jonathan Palmer to discuss the company’s fragment-based liquid biopsy technology and the immense opportunity to save lives through early cancer detection. Starting with lung cancer via its FirstLook test, Delfi expects to expand more broadly into other cancer types and applications like monitoring with a focus on access and affordability. The conversation touches on the company’s core values and the large opportunity set afforded by recent funding rounds.

    See omnystudio.com/listener for privacy information.
    続きを読む 一部表示

あらすじ・解説

“Our mission is to make cancer less deadly through widely accessible next-generation early-detection blood tests.” Susan Tousi, CEO of Delfi Diagnostics, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Tousi joins BI analyst Jonathan Palmer to discuss the company’s fragment-based liquid biopsy technology and the immense opportunity to save lives through early cancer detection. Starting with lung cancer via its FirstLook test, Delfi expects to expand more broadly into other cancer types and applications like monitoring with a focus on access and affordability. The conversation touches on the company’s core values and the large opportunity set afforded by recent funding rounds.

See omnystudio.com/listener for privacy information.
続きを読む 一部表示

Delfi Diagnostics Marries Fragmentomics, Machine Learning in Cancer Detectionに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。